Twist Bioscience Corp (TWST) stock
TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 13/30345% above fair value
$152.78−20.67 (-11.92%)
Close on Oct 30, 2026Market cap $9.58BP/E –Yield –
Earnings
Twist Bioscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 13, 2026
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$118.40M
+23.2% on a year earlier
EPS, Q3 FY2026
–
$0.33 a year earlier
Latest guidance
Raised
Aug 3, 2026 · 4 items
Quarterly results
Revenue and earnings per share from each of Twist Bioscience's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Sep 30, 2026 | Nov 13, 2026Expected | – | – | – | – |
| Q3 FY2026ended Jun 30, 2026 | Aug 3, 2026before the open | $118.40M | +23.2% | – | Release |
| Q2 FY2026ended Mar 31, 2026 | May 4, 2026before the open | $110.70M | +19.3% | – | Release |
| Q1 FY2026ended Dec 31, 2025 | Feb 2, 2026before the open | $103.70M | +16.9% | -$0.50 | Release |
| Q4 FY2025ended Sep 30, 2025 | Nov 14, 2025before the open | $99.00M | +16.9% | -$0.45 | Release |
| Q3 FY2025ended Jun 30, 2025 | Aug 4, 2025before the open | $96.10M | +17.9% | $0.33 | Release |
| Q2 FY2025ended Mar 31, 2025 | May 5, 2025before the open | $92.80M | +23.2% | -$0.66 | Release |
| Q1 FY2025ended Dec 31, 2024 | Feb 3, 2025before the open | $88.70M | +24.1% | -$0.53 | Release |
| Q4 FY2024ended Sep 30, 2024 | Nov 18, 2024before the open | $84.70M | +26.6% | – | Release |
| Q3 FY2024ended Jun 30, 2024 | Aug 2, 2024before the open | $81.50M | +27.9% | -$1.47 | Release |
| Q2 FY2024ended Mar 31, 2024 | May 2, 2024after the close | $75.30M | +25.1% | -$0.79 | Release |
| Q1 FY2024ended Dec 31, 2023 | Feb 2, 2024before the open | $71.50M | +31.9% | -$0.75 | Release |
| Q4 FY2023ended Sep 30, 2023 | Nov 17, 2023before the open | $66.90M | +16.8% | -$0.81 | Release |
| Q3 FY2023ended Jun 30, 2023 | Aug 4, 2023before the open | $63.70M | +13.5% | -$1.01 | Release |
| Q2 FY2023ended Mar 31, 2023 | May 5, 2023before the open | $60.20M | +25.2% | -$1.04 | Release |
| Q1 FY2023ended Dec 31, 2022 | Feb 3, 2023before the open | $54.20M | +29.0% | -$0.74 | Release |
| Q4 FY2022ended Sep 30, 2022 | Nov 18, 2022before the open | $57.30M | +50.8% | -$0.91 | Release |
| Q3 FY2022ended Jun 30, 2022 | Aug 5, 2022before the open | $56.10M | – | -$1.08 | Release |
| Q2 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $48.10M | – | -$1.13 | Release |
| Q1 FY2022ended Dec 31, 2021 | Feb 4, 2022before the open | $42.00M | – | -$0.91 | Release |
| Q4 FY2021ended Sep 30, 2021 | Nov 22, 2021after the close | $38.00M | – | -$0.84 | Release |
| Q3 FY2021ended Jun 30, 2021 | Aug 6, 2021before the open | – | – | – | Filing |
| Q2 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Dec 31, 2020 | Feb 4, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Sep 30, 2020 | Nov 23, 2020before the open | – | – | – | Filing |
| Q3 FY2020ended Jun 30, 2020 | Aug 6, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Twist Bioscience's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| growth | Q4 FY2026 | +25% | – | New | Aug 3, 2026 |
| Total revenue | Q4 FY2026 | $123.00M – $124.00M | – | New | Aug 3, 2026 |
| growth | FY2026 | +21% | +17% – +19% | Raised | Aug 3, 2026 |
| Total revenue | FY2026 | $456.00M – $457.00M | $442.00M – $447.00M | Raised | Aug 3, 2026 |
| Total revenue | FY2026 | $435.00M – $440.00M | – | New | Feb 2, 2026 |
| G ross margin | FY2026 | 52% | – | New | Feb 2, 2026 |
| Gross margin | FY2026 | 52% | 52% | Reaffirmed | May 4, 2026 |
Guidance vs results
The last range Twist Bioscience gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $114.00M – $115.00M | $118.40M | Above range |
| Q3 FY2026 | Revenue growth | +19% | +23.2% | Above range |
| Q2 FY2026 | Revenue | $107.00M – $108.00M | $110.70M | Above range |
| Q1 FY2026 | Revenue | $100.00M – $101.00M | $103.70M | Above range |
| Q1 FY2026 | Revenue growth | +13% – +14% | +16.91% | Above range |
| FY2025 | Revenue | $374.00M – $376.00M | $376.60MΣ4Q | Above range |
| Q4 FY2025 | Revenue | $96.00M – $98.00M | $99.00M | Above range |
| Q3 FY2025 | Revenue | $94.00M – $97.00M | $96.10M | Within range |
| Q3 FY2025 | Revenue growth | +15% – +19% | +17.91% | Within range |
| Q2 FY2025 | Revenue | $91.00M – $93.00M | $92.80M | Within range |
| Q1 FY2025 | Revenue | $87.00M | $88.70M | Above range |
| Q1 FY2025 | Revenue growth | +26% | +24.06% | Below range |
| Q4 FY2024 | Revenue | $82.00M – $83.00M | $84.70M | Above range |
| Q3 FY2024 | Revenue | $77.00M | $81.50M | Above range |
| Q2 FY2024 | Revenue | $70.00M – $71.00M | $75.30M | Above range |
| Q1 FY2024 | Revenue | $67.00M – $68.00M | $71.50M | Above range |
| Q4 FY2023 | Revenue | $63.00M – $64.00M | $66.90M | Above range |
| Q3 FY2023 | Revenue | $60.00M – $61.00M | $63.70M | Above range |
| Q2 FY2023 | Revenue | $56.50M | $60.20M | Above range |
| Q1 FY2023 | Revenue | $54.00M | $54.20M | Above range |
| Q1 FY2022 | Revenue | $37.00M – $39.00M | $42.00M | Above range |
Guidance history
Every forecast Twist Bioscience put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 3, 2026 | growth | FY2026 | +21% | Raised |
| Aug 3, 2026 | Total revenue | FY2026 | $456.00M – $457.00M | Raised |
| Aug 3, 2026 | growth | Q4 FY2026 | +25% | New |
| Aug 3, 2026 | Total revenue | Q4 FY2026 | $123.00M – $124.00M | New |
| May 4, 2026 | Gross margin | FY2026 | 52% | Reaffirmed |
| May 4, 2026 | growth | FY2026 | +17% – +19% | Raised |
| May 4, 2026 | Total revenue | FY2026 | $442.00M – $447.00M | Raised |
| May 4, 2026 | growth | Q3 FY2026 | +19% | New |
| May 4, 2026 | Total revenue | Q3 FY2026 | $114.00M – $115.00M | New |
| Feb 2, 2026 | G ross margin | FY2026 | 52% | New |
| Feb 2, 2026 | T otal revenue | Q2 FY2026 | $107.00M – $108.00M | New |
| Feb 2, 2026 | Total revenue | FY2026 | $435.00M – $440.00M | New |
| Nov 14, 2025 | Gross margin | FY2026 | 52% | New |
| Nov 14, 2025 | Total revenue growth | FY2026 | +13% – +15.5% | New |
| Nov 14, 2025 | DNA Synthesis and Protein Solutions (previously SynBio and Biopharma) revenue growth | FY2026 | +15% – +18% | Raised |
| Nov 14, 2025 | NGS Applications (previously NGS) revenue growth | FY2026 | +11% – +13.5% | Lowered |
| Nov 14, 2025 | Total revenue | FY2026 | $425.00M – $435.00M | New |
| Nov 14, 2025 | DNA Synthesis and Protein Solutions (previously SynBio and Biopharma) revenue | FY2026 | $194.00M – $199.00M | Lowered |
| Nov 14, 2025 | NGS Applications (previously NGS) revenue | FY2026 | $231.00M – $236.00M | Raised |
| Nov 14, 2025 | Total revenue growth | Q1 FY2026 | +13% – +14% | New |
| Nov 14, 2025 | Total revenue | Q1 FY2026 | $100.00M – $101.00M | New |
| Aug 4, 2025 | Adjusted EBITDA | FY2025 | -$47.00M – -$45.00M | New |
| Aug 4, 2025 | Adjusted EBITDA | Q4 FY2025 | -$8.00M – -$6.00M | New |
| Aug 4, 2025 | Gross margin | FY2025 | 50.5% – 51% | New |
| Aug 4, 2025 | gross margin | Q4 FY2025 | 51% – 52% | Raised |
| Aug 4, 2025 | Total revenue | FY2025 | $374.00M – $376.00M | New |
| Aug 4, 2025 | Total revenue | Q4 FY2025 | $96.00M – $98.00M | New |
| May 5, 2025 | Adjusted EBITDA | Q3 FY2025 | -$13.00M | New |
| May 5, 2025 | Adjusted EBITDA | FY2025 | -$53.00M – -$48.00M | Raised |
| May 5, 2025 | gross margin | Q4 FY2025 | 50% | Reaffirmed |
| May 5, 2025 | Gross margin | FY2025 | 49.5% | Raised |
| May 5, 2025 | SynBio revenue growth | Q3 FY2025 | +12% – +18% | New |
| May 5, 2025 | NGS revenue growth | Q3 FY2025 | +18% – +20% | Raised |
| May 5, 2025 | Biopharma revenue growth | Q3 FY2025 | +18% | Lowered |
| May 5, 2025 | SynBio revenue | Q3 FY2025 | $37.00M – $39.00M | New |
| May 5, 2025 | NGS revenue | Q3 FY2025 | $51.00M – $52.00M | Raised |
| May 5, 2025 | Biopharma revenue | Q3 FY2025 | $6.00M | Lowered |
| May 5, 2025 | SynBio revenue growth | FY2025 | +17% – +19% | New |
| May 5, 2025 | NGS revenue growth | FY2025 | +21% – +24% | Raised |
| May 5, 2025 | Biopharma revenue growth | FY2025 | +13% | Lowered |
| May 5, 2025 | SynBio revenue | FY2025 | $144.00M – $147.00M | New |
| May 5, 2025 | NGS revenue | FY2025 | $205.00M – $209.00M | Raised |
| May 5, 2025 | Biopharma revenue | FY2025 | $23.00M | Lowered |
| May 5, 2025 | Total revenue growth | Q3 FY2025 | +15% – +19% | New |
| May 5, 2025 | Total revenue | Q3 FY2025 | $94.00M – $97.00M | New |
| May 5, 2025 | Total revenue growth | FY2025 | +19% – +21% | Raised |
| May 5, 2025 | Total revenue | FY2025 | $372.00M – $379.00M | Reaffirmed |
| Feb 3, 2025 | Adjusted EBITDA | Q2 FY2025 | -$16.00M | New |
| Feb 3, 2025 | Adjusted EBITDA | FY2025 | -$60.00M – -$55.00M | Raised |
| Feb 3, 2025 | Gross margin | FY2025 | 49% | Raised |
| Feb 3, 2025 | Total revenue | Q2 FY2025 | $91.00M – $93.00M | New |
| Feb 3, 2025 | Total revenue | FY2025 | $372.00M – $379.00M | Raised |
| Nov 18, 2024 | Adjusted EBITDA | Q1 FY2025 | -$20.00M | New |
| Nov 18, 2024 | Adjusted EBITDA | FY2025 | -$65.00M – -$60.00M | New |
| Nov 18, 2024 | gross margin | Q4 FY2025 | 50% | New |
| Nov 18, 2024 | Gross margin | FY2025 | 48% | New |
| Nov 18, 2024 | SynBio revenue growth | Q1 FY2025 | +26% | New |
| Nov 18, 2024 | NGS revenue growth | Q1 FY2025 | +22% | Lowered |
| Nov 18, 2024 | Total revenue | Q1 FY2025 | $87.00M | New |
| Nov 18, 2024 | SynBio revenue | Q1 FY2025 | $34.00M | Lowered |
| Nov 18, 2024 | NGS revenue | Q1 FY2025 | $48.00M | Raised |
| Nov 18, 2024 | Biopharma revenue | Q1 FY2025 | $5.00M | Lowered |
| Nov 18, 2024 | Total revenue growth | FY2025 | +17% – +20% | New |
| Nov 18, 2024 | SynBio revenue growth | FY2025 | +15% – +18% | Lowered |
| Nov 18, 2024 | NGS revenue growth | FY2025 | +20% – +24% | Raised |
| Nov 18, 2024 | Biopharma revenue growth | FY2025 | +5% – +8% | Lowered |
| Nov 18, 2024 | Total revenue | FY2025 | $367.00M – $377.00M | New |
| Nov 18, 2024 | SynBio revenue | FY2025 | $142.00M – $146.00M | Lowered |
| Nov 18, 2024 | NGS revenue | FY2025 | $204.00M – $209.00M | Raised |
| Nov 18, 2024 | Biopharma revenue | FY2025 | $21.00M – $22.00M | Lowered |
| Aug 2, 2024 | Capital expenditure | FY2024 | $13.00M | Lowered |
| Aug 2, 2024 | Adjusted EBITDA loss | Q4 FY2024 | -$20.00M | New |
| Aug 2, 2024 | Gross margin | Q4 FY2024 | 44% | Raised |
| Aug 2, 2024 | Gross margin | FY2024 | 42% | Raised |
| Aug 2, 2024 | Loss from operations before taxes | FY2024 | -$230.00M – -$227.00M | New |
| Aug 2, 2024 | loss from operations | FY2024 | -$185.00M – -$182.00M | New |
| Aug 2, 2024 | Total revenue | Q4 FY2024 | $82.00M – $83.00M | Raised |
| Aug 2, 2024 | Total revenue | FY2024 | $310.00M – $311.00M | Raised |
| May 2, 2024 | Capital expenditure | FY2024 | $15.00M | Reaffirmed |
| May 2, 2024 | Gross margin | Q3 FY2024 | 41% – 42% | New |
| May 2, 2024 | Gross margin | Q4 FY2024 | 43% – 44% | New |
| May 2, 2024 | Gross margin | FY2024 | 41.5% – 42% | Raised |
| May 2, 2024 | Loss from operations before taxes | FY2024 | $183.00M – $188.00M | Lowered |
| May 2, 2024 | Total revenue | Q3 FY2024 | $77.00M | New |
| May 2, 2024 | Total revenue | Q4 FY2024 | $77.00M – $80.00M | Raised |
| May 2, 2024 | Total revenue | FY2024 | $300.00M – $304.00M | Raised |
| Feb 2, 2024 | Capital expenditure | FY2024 | $15.00M | Lowered |
| Feb 2, 2024 | Gross margin | Q2 FY2024 | 39% | New |
| Feb 2, 2024 | Gross margin | FY2024 | 40% – 41% | Raised |
| Feb 2, 2024 | Loss from operations before taxes | FY2024 | $189.00M – $194.00M | Raised |
| Feb 2, 2024 | Ending cash, cash equivalents and short-term investments | FY2024 | $245.00M | Lowered |
| Feb 2, 2024 | Total revenue | Q2 FY2024 | $70.00M – $71.00M | New |
| Feb 2, 2024 | Total revenue | FY2024 | $288.00M – $293.00M | Raised |
| Nov 17, 2023 | Capital expenditure | FY2024 | $20.00M | Lowered |
| Nov 17, 2023 | Gross margin | Q1 FY2024 | 38% – 39% | New |
| Nov 17, 2023 | Gross margin | FY2024 | 39% – 40% | Lowered |
| Nov 17, 2023 | Loss from operations | Q1 FY2024 | $47.00M – $48.00M | New |
| Nov 17, 2023 | Loss from operations | Q4 FY2024 | $38.00M – $40.00M | New |
| Nov 17, 2023 | Loss from operations before taxes | FY2024 | $180.00M – $188.00M | Raised |
| Nov 17, 2023 | Total revenue | Q1 FY2024 | $67.00M – $68.00M | New |
| Nov 17, 2023 | Total revenue | Q4 FY2024 | $78.00M | New |
| Nov 17, 2023 | Total revenue | FY2024 | $285.00M – $290.00M | Lowered |
| Aug 4, 2023 | Capital expenditure | FY2023 | $35.00M | Lowered |
| Aug 4, 2023 | Gross margin | Q4 FY2023 | 36% | Reaffirmed |
| Aug 4, 2023 | Gross margin | FY2023 | 36% | Raised |
| Aug 4, 2023 | Revenue | Q4 FY2023 | $63.00M – $64.00M | Raised |
| Aug 4, 2023 | Revenue | FY2023 | $241.00M – $242.00M | Raised |
| May 5, 2023 | Capital expenditure | FY2023 | $40.00M | Lowered |
| May 5, 2023 | Gross margin | Q3 FY2023 | 30% | New |
| May 5, 2023 | Gross margin | Q4 FY2023 | 36% | New |
| May 5, 2023 | Gross margin | FY2023 | 35% – 36% | Lowered |
| May 5, 2023 | Operating loss | FY2023 | $230.00M – $234.00M | Raised |
| May 5, 2023 | Revenue | Q3 FY2023 | $60.00M – $61.00M | New |
| May 5, 2023 | Revenue | Q4 FY2023 | $62.00M – $63.00M | New |
| May 5, 2023 | Revenue guidance | FY2023 | $235.00M – $238.00M | Lowered |
| Feb 3, 2023 | Capital expenditure | FY2023 | $50.00M | Reaffirmed |
| Feb 3, 2023 | Capital expenditure | FY2024 | $40.00M | Reaffirmed |
| Feb 3, 2023 | Gross margin | Q2 FY2023 | 30% | New |
| Feb 3, 2023 | Gross margin | FY2023 | 39% – 40% | Reaffirmed |
| Feb 3, 2023 | Gross margin | FY2024 | 49% | Reaffirmed |
| Feb 3, 2023 | Operating loss | FY2023 | -$225.00M | New |
| Feb 3, 2023 | Operating loss | FY2024 | -$215.00M | Reaffirmed |
| Feb 3, 2023 | Operating expenses | FY2023 | $330.00M | New |
| Feb 3, 2023 | Operating expenses | FY2024 | $386.00M | New |
| Feb 3, 2023 | Revenue | Q2 FY2023 | $56.50M | New |
| Feb 3, 2023 | Revenue | FY2023 | $261.00M – $269.00M | Reaffirmed |
| Feb 3, 2023 | Revenue | FY2024 | $350.00M | Reaffirmed |
| Nov 18, 2022 | Capital expenditure | FY2023 | $50.00M | New |
| Nov 18, 2022 | Capital expenditure | FY2024 | $40.00M | New |
| Nov 18, 2022 | Gross margin | FY2023 | 39% – 40% | New |
| Nov 18, 2022 | Gross margin | FY2024 | 49% | New |
| Nov 18, 2022 | Operating loss | FY2024 | -$215.00M | New |
| Nov 18, 2022 | Revenue | Q1 FY2023 | $54.00M | New |
| Nov 18, 2022 | Revenue | FY2023 | $261.00M – $269.00M | New |
| Nov 18, 2022 | Revenue | FY2024 | $350.00M | New |
| Aug 5, 2022 | Capital expenditures | FY2022 | $95.00M – $100.00M | Raised |
| Aug 5, 2022 | Gross margin | FY2022 | 40% | New |
| Aug 5, 2022 | NGS revenue | FY2022 | $97.00M | Raised |
| Aug 5, 2022 | Biopharma revenue | FY2022 | $26.00M | Lowered |
| Aug 5, 2022 | Operating expenses | FY2022 | $330.00M | Raised |
| Aug 5, 2022 | Net loss | FY2022 | $250.00M | Lowered |
| Aug 5, 2022 | R&D expense | FY2022 | $125.00M | Lowered |
| Aug 5, 2022 | R&D expense for DNA data storage | FY2022 | $40.00M | Lowered |
| Aug 5, 2022 | Stock-based compensation | FY2022 | $80.00M | Raised |
| Aug 5, 2022 | Depreciation | FY2022 | $14.00M | Lowered |
| Aug 5, 2022 | SynBio revenue | FY2022 | $80.00M | Raised |
| Aug 5, 2022 | Revenue | FY2022 | $203.00M | Raised |
| May 5, 2022 | Capital expenditures | FY2022 | $90.00M – $100.00M | Raised |
| May 5, 2022 | Gross margin | FY2022 | 37% | Raised |
| May 5, 2022 | gross margin | FY2022 | 42% – 44% | Reaffirmed |
| May 5, 2022 | Revenue | FY2022 | $191.00M – $199.00M | Raised |
| Feb 4, 2022 | Capital expenditures | FY2022 | $80.00M – $90.00M | Reaffirmed |
| Feb 4, 2022 | Gross margin | FY2022 | 35% – 37% | Reaffirmed |
| Feb 4, 2022 | Gross margin | FY2022 | 42% – 44% | Reaffirmed |
| Feb 4, 2022 | SynBio revenue | FY2022 | $70.00M – $72.00M | Raised |
| Feb 4, 2022 | NGS revenue | FY2022 | $94.00M – $96.00M | Raised |
| Feb 4, 2022 | Biopharma revenue | FY2022 | $25.00M – $30.00M | Lowered |
| Feb 4, 2022 | Operating expenses | FY2022 | $335.00M | Raised |
| Feb 4, 2022 | Net loss | FY2022 | $260.00M | Lowered |
| Feb 4, 2022 | R&D | FY2022 | $130.00M | Lowered |
| Feb 4, 2022 | Stock-based compensation | FY2022 | $74.00M | Lowered |
| Feb 4, 2022 | Depreciation | FY2022 | $13.00M | Lowered |
| Feb 4, 2022 | Revenue | FY2022 | $189.00M – $198.00M | Raised |
| Nov 22, 2021 | Capital expenditures | FY2022 | $80.00M – $90.00M | New |
| Nov 22, 2021 | Gross margin | FY2022 | 42% – 44% | New |
| Nov 22, 2021 | Gross margin | FY2022 | 35% – 37% | New |
| Nov 22, 2021 | Biopharma revenue | FY2022 | $22.00M – $27.00M | Lowered |
| Nov 22, 2021 | Operating expenses | FY2022 | $315.00M | Raised |
| Nov 22, 2021 | Net loss | FY2022 | $250.00M | Lowered |
| Nov 22, 2021 | Stock-based compensation | FY2022 | $47.00M | Lowered |
| Nov 22, 2021 | Depreciation | FY2022 | $13.00M | Lowered |
| Nov 22, 2021 | R&D | FY2022 | $130.00M | Lowered |
| Nov 22, 2021 | Synbio revenue | FY2022 | $67.00M – $70.00M | New |
| Nov 22, 2021 | NGS revenue | FY2022 | $94.00M – $96.00M | Raised |
| Nov 22, 2021 | Revenue | FY2022 | $183.00M – $193.00M | New |
| Nov 22, 2021 | Revenue | Q1 FY2022 | $37.00M – $39.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Twist Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results